Clinical Trial Update: Docosahexaenoic Acid (DHA) Administration and Length of Gestation: a Feasibility Study [NA]

View source ↗

Summary

A feasibility trial evaluating docosahexaenoic acid (DHA) administration and length of gestation in premature birth has been withdrawn. The sponsor is Kaiser Pe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Birth

Drugs mentioned

• Docosahexaenoic acid (DHA) (docosahexaenoic acid)

Snippet

Sponsor: Kaiser Permanente | Conditions: Premature Birth | NA | Status: WITHDRAWN